Vivesto AB (OM: VIVE)
Health Care · Biotechnology · SE
Skr7.21
-3.74% today · -68.9% 1Y
Vivesto AB (OM: VIVE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.06M and employs 4 people.
Over the last twelve months the share price has lost 68.9%, trading between 7.00 and 27.30.
Tweenvest scores Vivesto AB across four factors: quality 41/100, value 55/100. Its strongest factor is value.
VIVE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.06M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.07
- Dividend yield
- —
- Beta (5Y)
- 0.88
- 52-week high
- Skr27.30
- 52-week low
- Skr7.00
- Avg volume (3M)
- —
- Shares outstanding
- 11.07M
- Employees
- 4
- Next earnings
- —
About Vivesto AB
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
- ISIN
- SE0028925701
- Founded
- 1988
- Listed since
- Jun 24, 2010
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Active Biotech AB (publ)OM: ACTI | $8.34M | Skr3.14 | -10.94% |
| MetaVia Inc.NasdaqCM: MTVA | $8.30M | $1.26 | -10.64% |
| MOA Life Plus Co. Ltd.KOSDAQ: A142760 | $8.22M | ₩520.00 | +0.78% |
| NFL Biosciences SAENXTPA: ALNFL | $8.08M | €0.57 | -8.55% |
| OSR Health, Inc.OTCPK: OSRH | $7.94M | $0.23 | +15.90% |
| Delta-Fly Pharma, Inc.TSE: 4598 | $7.86M | ¥84.00 | -15.15% |
| OptiBiotix Health PlcAIM: OPTI | $7.79M | £0.06 | -4.24% |
| Bolt Biotherapeutics, Inc.NasdaqCM: BOLT | $7.71M | $4.00 | -2.68% |
Figures last refreshed Oct 18, 2026.